James Bochnowski Net Worth

The estimated Net Worth of James J Bochnowski is at least $284 Thousand dollars as of 17 May 2023. Mr. Bochnowski owns over 1,280 units of Jaguar Health Inc stock worth over $2,557 and over the last 21 years he sold JAGX stock worth over $777. In addition, he makes $280,373 as Independent Chairman of the Board at Jaguar Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Bochnowski JAGX stock SEC Form 4 insiders trading

James has made over 7 trades of the Jaguar Health Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 1,280 units of JAGX stock worth $1,446 on 17 May 2023.

The largest trade he's ever made was buying 180,582 units of Jaguar Health Inc stock on 23 July 2019 worth over $361,164. On average, James trades about 29,307 units every 126 days since 2003. As of 17 May 2023 he still owns at least 2,263 units of Jaguar Health Inc stock.

You can see the complete history of Mr. Bochnowski stock trades at the bottom of the page.

James Bochnowski biography

James J. Bochnowski serves as Independent Chairman of the Board of the Company. Mr. Bochnowski has served as the founder and Managing Member of Delphi Ventures, a venture capital firm. In 1980, Mr. Bochnowski co-founded Technology Venture Investors. Mr. Bochnowski holds an M.B.A. from Harvard University Graduate School of Business and a B.S. in Aeronautics and Astronautics from Massachusetts Institute of Technology.

What is the salary of James Bochnowski?

As the Independent Chairman of the Board of Jaguar Health Inc, the total compensation of James Bochnowski at Jaguar Health Inc is $280,373. There are 6 executives at Jaguar Health Inc getting paid more, with Lisa Conte having the highest compensation of $1,433,160.

How old is James Bochnowski?

James Bochnowski is 76, he's been the Independent Chairman of the Board of Jaguar Health Inc since 2018. There are no older and 14 younger executives at Jaguar Health Inc.

What's James Bochnowski's mailing address?

James's mailing address filed with the SEC is C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO, CA, 94104.

Insiders trading at Jaguar Health Inc

Over the last 9 years, insiders at Jaguar Health Inc have traded over $596,652 worth of Jaguar Health Inc stock and bought 670,772 units worth $1,311,594 . The most active insiders traders include Capital Partners, L.P.Sagar..., James J Bochnowski, and Investments Ltd Burford Cap.... On average, Jaguar Health Inc executives and independent directors trade stock every 66 days with the average trade being worth of $27,901. The most recent stock trade was executed by Pravin R Chaturvedi on 17 May 2024, trading 871 units of JAGX stock currently worth $984.

What does Jaguar Health Inc do?

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/

Complete history of Mr. Bochnowski stock trades at Jaguar Health Inc

Jaguar Health Inc executives and stock owners

Jaguar Health Inc executives and other stock owners filed with the SEC include:

• Lisa Conte,
  President, Chief Executive Officer, Director
• Steven King,
  Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary
• Lisa A. Conte,
  Founder, CEO, Pres & Director
• Jonathan Wolin,
  Chief of Staff, General Counsel and Chief Compliance Officer
• Jonathan S. Wolin CPA, J.D., M.B.A.,
  Chief of Staff, Chief Compliance Officer & Gen. Counsel
• Dr. Steven R. King,
  Chief Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.
• James Bochnowski,
  Independent Chairman of the Board
• Jonathan Siegel,
  Independent Director
• Jiahao Qiu,
  Independent Director
• John Micek,
  Independent Director
• Gregory Divis,
  Independent Director
• Melissa Yeager,
  Senior Vice President - Regulatory Affairs & Quality Assurance
• Carol Lizak,
  Senior Vice President - Finance, Chief Accounting Officer
• Melissa A. Yeager J.D.,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Ian H. Wendt M.B.A.,
  Chief Commercial Officer
• David Sesin,
  Chief Manufacturing Officer
• Dr. Karen Brunke Ph.D.,
  Exec. VP of Corp. & Bus. Devel.
• Peter Hodge,
  Sr. Director of Investor Relations, Bus. Devel. & Special Events
• Dr. Pravin R. Chaturvedi Ph.D.,
  Chair of Scientific Advisory Board & Acting Chief Scientific Officer
• Carol R. Lizak,
  Chief Financial Officer
• Roger J. Waltzman,
  Chief Scientific Officer
• Folkert W. Kamphuis,
  Director
• Philippe Brianceau,
  Chief Veterinary Officer
• Murray David Mac Naughtan,
  
• Zhi Yang,
  Director
• Ari Azhir,
  Director
• Karen Steil Wright,
  CFO and Treasurer
• Jeffery C. Johnson,
  
• Jonathan M Glaser,
  
• Bryan Bryan Ezralow 1994 Tr...,
  
• Investments Ltd Burford Cap...,
  
• Capital Partners, L.P.Sagar...,
  
• John A Kallassy,
  CFO, COO, Treasurer
• Management, Ltd.Kunlun Phar...,
  
• Michael Hauser,
  Chf Veterinarian, Clinical Ops
• Anula Jayasuriya,
  Director
• Pravin R Chaturvedi,
  Chief Scientific Officer